多组学分析LOXL2 在肺腺癌诊断和预后评估中的作用

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (2065 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective To investigate the role of lysyl oxidase-like 2(LOXL2)in the diagnosis and prognosis of lung adenocarcinoma by analyzing the expression,genomic changes,prognosis and immune infiltration of LOXL2 in multiple databases.Methods LOXL2 expression was analyzed by TIMER,UALCAN,GEPIA and Kaplan-Meier databases and survival analysis was performed.Genomic changes of LOXL2 in lung adenocarcinoma patients were analyzed using cBioPortal database.The correlation between LOXL2 and immune cell infiltration and immune checkpoint was analyzed by TIMER.The protein expression of LOXL2 in normal lung tissue and lung adenocarcinoma tissue was described using HPA database.Results The mRNA and protein levels of LOXL2 in lung adenocarcinoma were higher than those in normal tissues.High expression of LOXL2 was associated with a later stage and poorer prognosis of lung adenocarcinoma.The rate of genetic change in LOXL2 was 6%.LOXL2 was strongly associated with partial immune cell infiltration and immune checkpoints (programmed cell death protein-1 [PD-1]and cytotoxic T lymphocyte-associated antigen 4 [CTLA-4])in lung adenoma.Immunohistochemistry showed that the protein expression of LOXL2 in lung adenocarcinoma was higher than that in normal lung tissue.Conclusion Through multi-omics data mining,LOXL2 is highly expressed in lung adenocarcinoma tissues,and is associated with immune cell infiltration and poor prognosis of patients.LOXL2 can be used as a novel biomarker for diagnosis and prognosis of lung adenocarcinoma.

Key words： Lung adenocarcinoma Lysyl oxidase-like 2 Multi-omics Immune infiltration Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I16/15

[1]	Sung H，Ferlay J，Siegel RL，et al.Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin，2021，71（3）：209-249.
[2]	Nicholson AG，Moreira AL，Mino-Kenudson M，et al.Grading in Lung Adenocarcinoma：Another New Normal[J].J Thorac Oncol，2021，16（10）：1601-1604.
[3]	Sperduto PW，Yang TJ，Beal K，et al.Estimating Survival in Patients With Lung Cancer and Brain Metastases：An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers（Lung-molGPA）[J].JAMA Oncol，2017，3（6）：827-831.
[4]	Li H，Wang W，Jia H，et al.Prognostic model for brain metastases from lung adenocarcinoma identified with epidermal growth factor receptor mutation status[J].Thorac Cancer，2017，8（5）：436-442.
[5]	梁丽金，赵睿学，王上，等.LOXL2 基因与结直肠癌临床预后及免疫浸润相关性分析[J].重庆医学，2022，51（17）：3010-3015.
[6]	Ahn SG，Dong SM，Oshima A，et al.LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients[J].Breast Cancer Res Treat，2013，141（1）：89-99.
[7]	Wen B，Xu LY，Li EM.LOXL2 in cancer：regulation，downstream effectors and novel roles[J].Biochim Biophys Acta Rev Cancer，2020，1874（2）：188435.
[8]	Li R，Li H，Zhu L，et al.Reciprocal regulation of LOXL2 and HIF1α drives the Warburg effect to support pancreatic cancer aggressiveness[J].Cell Death Dis，2021，12（12）：1106.
[9]	Wu F，Wang L，Zhou C.Lung cancer in China：current and prospect[J].Curr Opin Oncol，2021，33（1）：40-46.
[10]	王晨洁，顾海迪，谭洁.帕博利珠单抗联合培美曲塞+顺铂化疗方案在晚期肺腺癌中的应用效果[J].中国当代医药，2022，29（18）：27-30，35.
[11]	李莹莹，詹丽芬，吴登鹏，等.KRAS 突变晚期肺腺癌患者一线治疗的回顾性观察研究[J].中国当代医药，2023，30（36）：99-103，111，197-198.
[12]	马俊，房兵，张长松.血浆EGFR 外显子19 和21 突变指导进展期肺腺癌的靶向治疗[J].中国医药科学，2024，14（4）：5-8，46.
[13]	Hoy H，Lynch T，Beck M.Surgical Treatment of Lung Cancer[J].Crit Care Nurs Clin North Am，2019，31（3）：303-313.
[14]	Xu JY，Zhang C，Wang X，et al.Integrative Proteomic Characterization of Human Lung Adenocarcinoma[J].Cell，2020，182（1）：245-261.
[15]	Gillette MA，Satpathy S，Cao S，et al.Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma[J].Cell，2020，182（1）：200-225.
[16]	Zhao N，Chen C，Guo Y，et al.LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry[J].Dig Liver Dis，2023，55（5）：661-672.
[17]	Wu L，Zhu Y.The function and mechanisms of action of LOXL2 in cancer（Review）[J].Int J Mol Med，2015，36（5）：1200-1204.
[18]	Peng T，Lin S，Meng Y，et al.LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing LOXL2-induced epithelial-mesenchymal transition（EMT）[J].Cell Cycle，2022，21（17）：1827-1841.
[19]	LinZY，ChuangYH，ChuangWL.Cancer-associatedfibroblasts up-regulate CCL2，CCL26，IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells[J].Biomed Pharmacother，2012，66（7）：525-529.
[20]	赵秋荣，郭静，陈良远.利用TCGA 数据集分析E2F7 在肺腺癌中的表达及临床意义[J].中国当代医药，2021，28（27）：130-132，封4.
[21]	Spella M，Stathopoulos GT.Immune Resistance in Lung Adenocarcinoma[J].Cancers，2021，13（3）：384.
[22]	Yang Y.Cancer immunotherapy：harnessing the immune systemtobattlecancer[J].JClinInvest，2015，125（9）：3335-3337.
[23]	Lahiri A，Maji A，Potdar PD，et al.Lung cancer immunotherapy：progress，pitfalls，and promises[J].Mol Cancer，2023，22（1）：40.
[24]	Sun N，Luo Y，Zheng B，et al.A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma[J].J Transl Med，2022，20（1）：332.
[25]	Zhu H，Zheng C，Liu H，et al.Significance of macrophage infiltration in the prognosis of lung adenocarcinoma patients evaluated by scRNA and bulkRNA analysis[J].Front Immunol，2022，13：1028440.
[26]	徐歆宇，赵朝芬，贺前勇，等.外周血PD-1、CTLA-4、T-reg、pDC 与鼻咽癌患者临床特征及疗效的相关性[J].现代肿瘤医学，2024，32（1）：53-60.